{"id":5611,"date":"2022-01-31T07:49:55","date_gmt":"2022-01-31T07:49:55","guid":{"rendered":"https:\/\/lynxee.consulting\/?p=5611"},"modified":"2023-01-26T16:02:34","modified_gmt":"2023-01-26T16:02:34","slug":"france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products","status":"publish","type":"post","link":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/","title":{"rendered":"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products"},"content":{"rendered":"<p style=\"text-align: justify\"><span style=\"font-weight: 400\">As a result of the entry into force of Implementing <\/span><a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32021R1379&amp;from=FR\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">Regulation (EU) 2021\/1379<\/span><\/a><span style=\"font-weight: 400\"> of 19 August 2021 concerning the <\/span><b>non-renewal of famoxadone approval<\/b><span style=\"font-weight: 400\">, the last authorisation containing this substance is withdrawn from 16 March 2022 (decision of 10.01.2022).<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">The end of sales and distribution is set on 16.03.2022.<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">The end of use of the stocks of products is set on 16.09.2022.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">In addition, further to the expiry of the approval of the active substances <\/span><b>acrinathrin <\/b><span style=\"font-weight: 400\">and <\/span><b>prochloraz<\/b><span style=\"font-weight: 400\">, 15 authorisations and 5 parallel trade permits for plant protection products containing these substances were withdrawn from 31 December 2021 (decisions of 17.12.2021 and 10.01.2022).<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">The end of sales and distribution is set on 30.06.2022.<\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-weight: 400\">The end of use of the stocks of products is set on 31.12.2022.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: justify\"><b>To download:\u00a0<\/b><\/p>\n<p style=\"text-align: justify\"><a href=\"https:\/\/ephy.anses.fr\/var\/default\/files\/liste_retraits_prochloraz.xlsx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">List of withdrawal of products<\/span><\/a> <i><span style=\"font-weight: 400\">(in French)<\/span><\/i><\/p>\n<p style=\"text-align: justify\"><b>Lynxee consulting<\/b><span style=\"font-weight: 400\">\u2019s team is at your disposal to answer your questions.<\/span><\/p>\n<p style=\"text-align: justify\"><b>Contact us!<\/b> <a href=\"http:\/\/lynxee.consulting\/en\/contact\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">http:\/\/lynxee.consulting\/en\/contact\/<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n<h6>Photo credit : congerdesign\/pixabay<\/h6>\n","protected":false},"excerpt":{"rendered":"<p>As a result of the entry into force of Implementing Regulation (EU) 2021\/1379 of 19 August 2021 concerning the non-renewal of famoxadone approval, the last authorisation<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":11,"featured_media":4548,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[352,353,354,351],"class_list":["post-5611","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulation","tag-acrinathrin","tag-famoxadone-en","tag-prochloraz-en","tag-withdrawal-of-products"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products - Lynxee consulting<\/title>\n<meta name=\"description\" content=\"As a result of the entry into force of Implementing Regulation (EU) 2021\/1379 of 19 August 2021 concerning the non-renewal of famoxadone approval, the\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products - Lynxee consulting\" \/>\n<meta property=\"og:description\" content=\"As a result of the entry into force of Implementing Regulation (EU) 2021\/1379 of 19 August 2021 concerning the non-renewal of famoxadone approval, the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/\" \/>\n<meta property=\"og:site_name\" content=\"Lynxee consulting\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-31T07:49:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-26T16:02:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/12\/sunrise-3742275_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"730\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tanalou Djae\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tanalou Djae\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/\"},\"author\":{\"name\":\"Tanalou Djae\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/da8f9efd807b456019d890b71820bbd4\"},\"headline\":\"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products\",\"datePublished\":\"2022-01-31T07:49:55+00:00\",\"dateModified\":\"2023-01-26T16:02:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/\"},\"wordCount\":152,\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/sunrise-3742275_1920.jpg\",\"keywords\":[\"acrinathrin\",\"famoxadone\",\"prochloraz\",\"withdrawal of products\"],\"articleSection\":[\"Regulation\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/\",\"name\":\"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products - Lynxee consulting\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/sunrise-3742275_1920.jpg\",\"datePublished\":\"2022-01-31T07:49:55+00:00\",\"dateModified\":\"2023-01-26T16:02:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/da8f9efd807b456019d890b71820bbd4\"},\"description\":\"As a result of the entry into force of Implementing Regulation (EU) 2021\\\/1379 of 19 August 2021 concerning the non-renewal of famoxadone approval, the\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/sunrise-3742275_1920.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/sunrise-3742275_1920.jpg\",\"width\":1920,\"height\":730},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/\",\"name\":\"Lynxee consulting\",\"description\":\"Innovative support for regulatory issues\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lynxee.consulting\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/da8f9efd807b456019d890b71820bbd4\",\"name\":\"Tanalou Djae\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg\",\"caption\":\"Tanalou Djae\"},\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/author\\\/tanalou-djae\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products - Lynxee consulting","description":"As a result of the entry into force of Implementing Regulation (EU) 2021\/1379 of 19 August 2021 concerning the non-renewal of famoxadone approval, the","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/","og_locale":"en_US","og_type":"article","og_title":"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products - Lynxee consulting","og_description":"As a result of the entry into force of Implementing Regulation (EU) 2021\/1379 of 19 August 2021 concerning the non-renewal of famoxadone approval, the","og_url":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/","og_site_name":"Lynxee consulting","article_published_time":"2022-01-31T07:49:55+00:00","article_modified_time":"2023-01-26T16:02:34+00:00","og_image":[{"width":1920,"height":730,"url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/12\/sunrise-3742275_1920.jpg","type":"image\/jpeg"}],"author":"Tanalou Djae","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tanalou Djae","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/#article","isPartOf":{"@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/"},"author":{"name":"Tanalou Djae","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/da8f9efd807b456019d890b71820bbd4"},"headline":"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products","datePublished":"2022-01-31T07:49:55+00:00","dateModified":"2023-01-26T16:02:34+00:00","mainEntityOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/"},"wordCount":152,"image":{"@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/12\/sunrise-3742275_1920.jpg","keywords":["acrinathrin","famoxadone","prochloraz","withdrawal of products"],"articleSection":["Regulation"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/","url":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/","name":"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products - Lynxee consulting","isPartOf":{"@id":"https:\/\/lynxee.consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/#primaryimage"},"image":{"@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/12\/sunrise-3742275_1920.jpg","datePublished":"2022-01-31T07:49:55+00:00","dateModified":"2023-01-26T16:02:34+00:00","author":{"@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/da8f9efd807b456019d890b71820bbd4"},"description":"As a result of the entry into force of Implementing Regulation (EU) 2021\/1379 of 19 August 2021 concerning the non-renewal of famoxadone approval, the","breadcrumb":{"@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/#primaryimage","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/12\/sunrise-3742275_1920.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2020\/12\/sunrise-3742275_1920.jpg","width":1920,"height":730},{"@type":"BreadcrumbList","@id":"https:\/\/lynxee.consulting\/en\/france-withdrawal-of-acrinathrin-famoxadone-and-prochloraz-based-products\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/lynxee.consulting\/en\/"},{"@type":"ListItem","position":2,"name":"FRANCE: Withdrawal of acrinathrin, famoxadone and prochloraz-based products"}]},{"@type":"WebSite","@id":"https:\/\/lynxee.consulting\/#website","url":"https:\/\/lynxee.consulting\/","name":"Lynxee consulting","description":"Innovative support for regulatory issues","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lynxee.consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/da8f9efd807b456019d890b71820bbd4","name":"Tanalou Djae","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2021\/10\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2021\/10\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2021\/10\/Photo_site-web_TDJ-Copie-e1638363904581-96x96.jpg","caption":"Tanalou Djae"},"url":"https:\/\/lynxee.consulting\/en\/author\/tanalou-djae\/"}]}},"_links":{"self":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/5611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/comments?post=5611"}],"version-history":[{"count":3,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/5611\/revisions"}],"predecessor-version":[{"id":6431,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/5611\/revisions\/6431"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media\/4548"}],"wp:attachment":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media?parent=5611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/categories?post=5611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/tags?post=5611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}